[2]
DaSilva EJ. The Colours of Biotechnology: Science, Development and Humankind. Electron J Biotechnol 2004; 7(3): 1-2.
[3]
De La Vega I, Requena J, Fernández-Gómez R. The colors of biotechnology in Venezuela: a bibliometric analysis. Technol Soc 2015; 42: 123-34.
[4]
Afzal H, Zahid K, Ali Q, et al. Role of Biotechnology in Improving Human Health. J Mol Biomark Diagn 2016; 7(6): 1-7.
[5]
Kafarski P. Rainbow code of biotechnology. Chemik 2012; 66(8): 814-6.
[6]
Kircher M. White biotechnology: ready to partner and invest in. Biotechnol J 2006; 1: 787-94.
[7]
Streltsova E, Linton JD. Biotechnology patenting in the BRICS countries: strategies and dynamics. Trends Biotechnol 2018; 36(7): 642-5.
[13]
Santos MO. Estimativa 2018: incidência de câncer no
Brasil. Rio de Janeiro: INCA (Instituto Nacional de
Câncer José Alencar Gomes da Silva) 2017.
[14]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): 359-86.
[15]
Athayde Filho PF, Barbosa Filho JM, Lira BF. Pharmaceutical
analogues of piperine for the treatment of
cancer. BR 102016019918-2 A2. 2016.
[16]
Garzioni PP, Guimarães RC, Guimarães JLCA. Pharmaceutical compounds for the treatment of cancer.
BR1020170136930A2. 2017.
[17]
Chandrasekhar J, Patel L, Perreault S, et al. A compound,
a pharmaceutically acceptable salt, isomer or a
mixture thereof, pharmaceutical composition, method
for treatment of a disease or condition, inhibition of
the activity of a polypeptide phosphatidylinositol 3-
kinase and inhibition of excessive or destructive immune
reactions or growth or proliferation of cancer
cells, kit, and, use of a compound, a pharmaceutically
acceptable salt, isomer or a mixture thereof.
BR102017 0194477A2, 2017.
[18]
Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999; 274(13): 8347-50.
[19]
Yíngchūn H, Yù W. kūn Z, Téng M, Qí W. Application
of miRNA-6126 as diagnostic marker of lung
cancer. CN106929599A, 2017.
[20]
Luánlìbiāo, Siyuan H. 3-O-(para-methanesulfonate
benzyl)-ascorbic acid with anticancer activity and
preparation method. CN107056733A. 2017.
[21]
Changhao C, Fanlin L, Li W, et al. Application of
apoptosis-inducing reagent in human breast cancer
cell . CN107260753A, 2017.
[22]
Huang C, Tzeng YM, Yeh CT, Wu THA. Method for
inhibiting growth of ovarian cancer cells.
US20180050012A1, 2017.
[23]
SokoloV PM, Sukhanova A, Nabiyev IR. Method for
directed destruction of cancer cells. RU2638446C1. 2016.
[24]
Self CH, Cook DB. Advances in immunoassay technology. Curr Opin Biotechnol 1996; 7(1): 60-5.
[26]
Shanrong L, Shuqun C, Kai C, et al. One kind opn,
gdf15, nse, trap5 e opg joint diagnostic kit.
CN107462720A. 2017.
[27]
Hao Z. Application of mirna in preparation of cancer
diagnostic kit. CN106834470A. 2017.
[28]
Lianwen Q, Yong F, Ping L, Wei Z, Yan C. Stable
angel differentiation method of acute coronary syndrome
and the diagnostic kit of the same.
US2018088132A1. 2018.
[29]
Hyun KJ, Soo J, Hoon S, Ki B, Jung JJ. Composition
of detecting biomarker for diagnosis degree of obesity
rapid diagnostic kit using the same and method for
diagnosis using the same. KR20180032830. 2018.
[31]
Hak CJ, Jin LW, Keun LS. Hiv 1,2,0 simultaneous
diagnosis kit for hiv type 1, 2 and 0 using immunochromatographic
assay and simultaneous diagnosis
method using the same. KR20180025830. 2018.
[32]
Aniz PAEA, Gotti TB, Piazza RMF, Rocha LB. A
method, device and kit for in vitro immunochromatographic
diagnosis of leptospirosis and / or for detection
of leptospiraspp infection; process for its preparation.
BR1020160206170A2. 2018.
[33]
Myung SS. Kit for detecting intestinal parasites and
detection method using the same. KR20180008836A. 2018.
[34]
Freire ML. Avaliação de desempenho e custos diretos
de kits comercialmentedisponíveis no Brasil e do
protótipo DAT-LPC para o diagnóstico da
leishmaniose visceral humana Dissertação Belo
Horizonte Fundação Oswaldo Cruz - Instituto René
Rachou 2017.
[35]
Dias DS, Ribeiro PAF, Nogueira LM, Silva ES, Gal-dino AS. Recombinant multiepitope protein, its process
of production and its applications related to
Leishmaniasis. BR1020140313311. 2014.
[36]
Dias DS, Ribeiro PAF, Nogueira LM, et al. Recombinant
multiepitope protein and its use for the diagnosis
and treatment of Leishmaniasis.
BR1020150161620. 2015.
[37]
Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. Vaccine 2014; 32: 2150-9.
[38]
Cunningham AL, Garçon N, Leo O, et al. Vaccine development: From concept to early clinical testing. Vaccine 2016; 34: 6655-64.
[39]
Kaech SM, Wherry EJ, Ahmed R. Vaccines: effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2: 251-62.
[40]
Serruto D, Adu-Bobie J, Capecchi B, Rappuoli R, Pizza M, Masignani V. Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens. J Biotechnol 2004; 113: 15-32.
[41]
Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem 2013; 8: 360-76.
[42]
Moyle PM. Progress in vaccine development. Curr Protoc Microbiol 2015; 36: 18-1.
[43]
Del Giudice G, Rappuoli R. Genetically derived toxoids for use as vaccines and adjuvants. Vaccine 1999; 17: 44-S52.
[44]
Ciaramella G. Ebola vaccine. WO2017015457A1. 2017.
[45]
Towner JS, Nichol ST, Comer JA, Ksiazek TG, Rollin PE. Human ebola virus species and compositions
and methods thereof. US20180002675A1. 2018.
[46]
Ciaramella G, John S, Bett AJ, Casimiro DR. Herpes
simplex virus vaccine. WO2017070623A1, 2017.
[47]
Ciaramella G, Huang EY, Babaoglu K, Flynn JA, Zhang L. Broad spectrum influenza virus vaccine.
WO2017070620, 2017.
[48]
Solodushko VG, Fouty B, Bitko V. Novel platform
dna vaccine. WO2017079625A1, 2017.
[49]
Chacornac I, Francon A, Vacus P. Vaccine composition
comprising ipv and cyclodextrins. WO20160123
85A1, 2016.
[50]
Giunchetti RC, Alves MLR, Dutra WO, et al. Vaccinal
composition containing crude extract of mosquito
intestinal proteins and obtaining process.
BR1020170278859, 2017.
[51]
Giunchetti RC, Leite JC, Silveira P. Peptide, vaccine
for flebotomyne control and uses. BR1020170
229068, 2017.
[52]
Pereira LV. A importância do uso das células-tronco para a saúde pública. Cien Saude Colet 2008; 13: 7-14.
[53]
Rose N. The politics of life itself: biomedicine, power
and subjectivity in the twenty-first century 1 ed Oxford:
Princeton University Press 2006.
[54]
Zorzanelli RT, Speroni AV, Menezes RA, Leibing A. Stem cell research in Brazil: the production of a new field of Science. Hist Cienc Saude Manguinhos 2017; 24: 129-44.
[55]
Brotas CLC. Stem cell patents: a bioethical look. Rev Brasil Dir Anim 2014; 01: 219-75.
[56]
Aharonowiz M, Einstein O, Reubinoff B, Ben-Hur T. Human stem cell-derived neural precursors for treatment
of autoimmune diseases of the central nervous
system. US20180322. 2018.
[57]
Sun X, Lim B. Generation of functional cells from
stem cells. US20180072988, 2018.
[58]
Roux P. Reprogramming Method for producing induced
pluripotent stem cells (iPSC).
US20180023056, 2018.
[59]
Ikeyama Y, Okubo T, Nishida H, Tsuda T, Uno E, Yumoto M. Mesenchymal stem cell culture medium,
methods for culturing mesenchymal stem cells, and
mesenchymal stem cells. US20180066231, 2018.
[60]
Tremolada C, Ventura C, Graves M. Method and device
for preparing non-embryonic stem cells.
US20180066232, 2018.
[61]
Eto K, Endo H, Shigemori T. Method for producing
stem cell clones suitable for induction of differentiation
into somatic cells. US20180051260, 2018.
[62]
Wang J, Chen SK, Lin MS, Yen Y. Method for increasing
number of stem cells in human or animal
bodies. US20180024122, 2018.
[63]
Bos CVD, Reinisch B, Schenk J, Rosenbaum C. Compositions and methods for enhancing the therapeutic
potential of stem cells. US20180055888, 2018.
[64]
Giunchetti RC, Orefice RL, Lima TH, Batista MA, Silveira DL, Martins-Filho OA. Hybrid polymeric
companies of polycaprolactone and gelatine and process
of obtaining. BR1020170283747, 2017.
[65]
Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157: 220-33.
[66]
Suzuki M, Kato C, Kato A. Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. J Toxicol Pathol 2015; 28: 133-9.
[67]
Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs 2018; 10: 183-203.
[68]
Gao Y. Monoclonal Antibodies and Its Application.
CN107987163A, 2018.
[69]
Rankin EB, Giaccia AJ. The receptor tyrosine kinase AXL in cancer progression. Cancers 2016; 8: 103-18.
[70]
Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012; 1: 36-42.
[71]
Yang G, Yu C. Anti-cd19 fully human antibodies or
antibody fragments, and methods and uses.
CN107880128A, 2018.
[72]
Jung G, Grosse-Hovest L. Methods of using bispecific
antibodes for treating b-cell-mediated autoimmune
diseases or Auto-reactive B-cells.
US9624310B2, 2017.
[73]
Grewal I, Khare S, Gresser M. Engineered antibodyinterferon
fusion molecules for treatment of autoimmune
diseases. US9783589B2, 2017.
[74]
Greenfield SA, Garcia-Rates S, Morril P. Antibodies
against the T14 peptide of acetylcholinesterase.
GB2541477A, 2017.
[75]
Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-17.
59
7
1